-
公开(公告)号：US11690879B2
公开(公告)日：2023-07-04
申请号：US17258256
申请日：2019-07-10
发明人： Patrice Cani , Tiphaine Le Roy
摘要： A bacterium belonging to a novel bacterial genus, Dysosmobacter. Also, the therapeutic, nutraceutical and cosmetic use thereof. The uses include methods for treating a disorder, promoting weight loss, decreasing food intake, increasing muscle mass, decreasing fat mass, increasing satiety, and/or decreasing weight gain associated with food intake in a subject, including administering to the subject at least one isolated bacterium belonging to the genus Dysosmobacter and/or a variant thereof and/or fragments thereof.
-
公开(公告)号：US20220151970A1
公开(公告)日：2022-05-19
申请号：US17428369
申请日：2020-02-06
IPC分类号： A61K31/215 , A61K31/19 , A61P33/02 , C12P15/00
摘要： The present invention relates to a method for the production of a (poly)hydroxylated pentacyclic triterpene composition including a 3-O-p-coumaroyl ester of tormentic acid from a plant suspension cell culture, to a pharmaceutical composition comprising at least 3-O-p-coumaroyl ester of tormentic acid for a use in the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes, and to 3-O-p-coumaroyl ester of tormentic acid for its use as an antiparasitic agent for the prevention and/or the treatment of trypanosomiasis, optionally in admixture with other (poly)hydroxylated pentacyclic triterpenes.
-
公开(公告)号：US20220064729A1
公开(公告)日：2022-03-03
申请号：US17523325
申请日：2021-11-10
发明人： Denis DUFRANE
IPC分类号： C12Q1/6881 , C12N5/0775 , G01N33/74 , G01N33/53 , G01N33/50
摘要： The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.
-
公开(公告)号：US11203785B2
公开(公告)日：2021-12-21
申请号：US15571461
申请日：2016-05-09
发明人： Denis Dufrane
IPC分类号： C12Q1/6881 , C12N5/0775 , G01N33/74 , G01N33/53 , G01N33/50
摘要： The present invention relates to a method for assessing, evaluating and/monitoring the purity of a mesenchymal stem cells preparation, in particular of an adipose stem cells preparation, comprising measuring the expression level of at least one growth factor.
-
公开(公告)号：US20210184470A1
公开(公告)日：2021-06-17
申请号：US17168810
申请日：2021-02-05
IPC分类号： H02J3/38 , G05B19/042 , H02J3/32 , H02J3/46
摘要： An example device includes a processor configured to receive a plurality of voltage values representing respective voltage magnitudes at voltage nodes in a first portion of a power system and determine, for each voltage node, a respective value of first and second voltage-constraint coefficients. The processor is also configured to receive a power value corresponding to a connection point of the first portion of the power system with a second portion of the power system and determine for the connection point, a respective value of first and second power-constraint coefficients. The processor is also configured to cause at least one energy resource connected to the first portion of the power system to modify an output power of the at least one energy resource based on the value of the first and second voltage-constraint coefficients for each voltage node and the value of the first and second power-constraint coefficients.
-
公开(公告)号：US10793627B2
公开(公告)日：2020-10-06
申请号：US16698833
申请日：2019-11-27
发明人： Sebastian van der Woning , Filip Borgions , Torsten Dreier , Lore Mariën , Gitte De Boeck , Stéphanie Liénart , Sophie Lucas , Pierre Coulie
摘要： The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.
-
公开(公告)号：US20200181276A1
公开(公告)日：2020-06-11
申请号：US16791937
申请日：2020-02-14
发明人： Sophie Lucas , Pierre Coulie , Julia Cuende Villasur , Laure Dumoutier , Jean-Christophe Renauld , Sebastian van der Woning , Michael Saunders , Hans De Haard , Gitte De Boeck
摘要： The present invention relates to a protein binding to GARP in the presence of TGF-β and uses thereof.
-
公开(公告)号：US20200155616A1
公开(公告)日：2020-05-21
申请号：US16709232
申请日：2019-12-10
发明人： Patrice CANI , Amandine EVERARD , Clara BELZER , Willem DE VOS
IPC分类号： A61K35/74 , A61K9/00 , A61K35/741
摘要： The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
-
![[18F]-LABELLED LACTATE DERIVATIVE AS PET RADIOTRACER](/abs-image/US/2019/08/22/US20190255002A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190255002A1
公开(公告)日：2019-08-22
申请号：US16331176
申请日：2017-09-08
IPC分类号： A61K31/19 , C07C59/115 , A61B6/03 , A61B6/00
摘要： A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is a [18F]-labelled lactate derivative. Also, a process for the radiosynthesis of the [18F]-labelled lactate derivative. Further, the use of the [18F]-labelled lactate derivative for imaging lactate uptake in living cells, especially in humans.
-
公开(公告)号：US20190160177A1
公开(公告)日：2019-05-30
申请号：US16263401
申请日：2019-01-31
摘要： The present invention relates to a compound comprising one or more PEG moieties, wherein said compound is a therapeutic agent active for treating a respiratory disease. The present invention also relates to a method for preventing and/or treating a respiratory disease in a subject in need thereof comprising the administration of a PEGylated therapeutic agent. Another object of the invention is a method for enhancing the bioavailability of a therapeutic agent, for enhancing the pulmonary residency of a therapeutic agent and/or for reducing the pulmonary clearance of a therapeutic agent, wherein said methods comprise the PEGylation of the therapeutic agent.
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.026 秒)
